You are here

  • Home
  • Archive
  • Volume 30, Issue 8
  • Correction: Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study

Article Text

Article menu

See original article:

Download PDFPDF

Miscellaneous
Correction: Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study
Free

https://doi.org/10.1136/ijgc-2019-000869corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Chase D, Huang HQ, Monk BJ, et al. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. Int J Gynecol Cancer 2020;30(5):596–601.

    Since the online publication of this article, the authors have noticed that their funding statement is incorrect. The correct funding statement is ‘This study was supported by NIH grants to NRG Oncology (1U10CA180822), NRG Operations (U10CA180868) and NIH NCORP grant (UG1CA189867).’